ReviewMedicine2026
Schizophyllum commune-associated allergic bronchopulmonary mycosis in a postoperative lung cancer patient: A case report and comprehensive literature review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Allergic bronchopulmonary mycosis caused byIDCases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSchizophyllum commune (S commune), a basidiomycetous fungus, is increasingly recognized as an important cause of allergic bronchopulmonary mycosis, particularly in immunocompetent individuals with a history of respiratory surgery, chronic sinusitis, or structural airway abnormalities. PATIENT CONCERNS: A 71-year-old female with a prior right upper lobectomy for lung cancer and a history of invasive fungal sinusitis presented with recurrent dyspnea, cough, and chest tightness. DIAGNOSES: The diagnosis was confirmed by fungal culture and 18S rRNA sequencing, along with significantly elevated total serum immunoglobulin E (541 IU/mL), specific immunoglobulin E to S commune (15.2 kU/L), and peripheral eosinophilia (8.0%).
interventionsThe patient was treated with voriconazole and inhaled corticosteroids/formoterol for asthma control. OUTCOMES: Marked improvement in symptoms and radiologic findings was observed after 1 month of treatment, with sustained improvement over 3 months. LESSONS: This case highlights the diagnostic challenges in distinguishing S commune-induced allergic bronchopulmonary mycosis and emphasizes the importance of considering this pathogen even in immunocompetent patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.